Injunctions for the Production of Empagliflozin
Pharma is a competitive industry and organisations within it are constantly looking to find new ways to get ahead and to reach every part of the market. However, there are lines that even competitors can't cross and this is something that can be seen in action in the recent successful injunctions won by Boehringer Ingelheim against Dr. Reddy's Labs and MSN Labs. The two Indian labs recently released low-priced versions of the German pharma company's anti-diabetes drug empagliflozin, despite the...
View full press release